Supplementary Online Content

Similar documents
Community. Profile Powell County. Public Health and Safety Division

Community. Profile Big Horn County. Public Health and Safety Division

Community. Profile Yellowstone County. Public Health and Safety Division

Supplementary Online Content

Community. Profile Lewis & Clark County. Public Health and Safety Division

Community. Profile Missoula County. Public Health and Safety Division

Community. Profile Anaconda- Deer Lodge County. Public Health and Safety Division

Community. Profile Carter County. Public Health and Safety Division

A Four-System Comparison of Patients With Chronic Illness: The Military Health System, Veterans Health Administration, Medicaid, and Commercial Plans

Satisfaction with care is an important, patient-centered

Efficacy of Pembrolizumab in Patients With Advanced Melanoma With Stable Brain Metastases at Baseline: A Pooled Retrospective Analysis

Urinary Tract Infection in Men

Summary of Package Insert 1

Metabolic syndrome (MetS) is defined by a group

key words: chronic obstructive pulmonary disease, beta agonists, Medicare, health care costs, health care utilization

Metformin and breast cancer stage at diagnosis: a population-based study

Mortality of patients with multiple sclerosis: a cohort study in UK primary care

T.S. Kurki a, *,U.Häkkinen b, J. Lauharanta c,j.rämö d, M. Leijala c

Metabolic Syndrome and Health-related Quality of Life in Obese Individuals Seeking Weight Reduction

Urinary Tract Infection in Women

PNEUMOVAX 23 is recommended by the CDC for all your appropriate adult patients at increased risk for pneumococcal disease 1,2 :

The burden of cirrhosis and impact of universal coverage public health care system in Thailand: Nationwide study

Health Coaching: A Preliminary Report on the Effects in Traumatic Brain Injury/Polytrauma Patients

CheckMate 153: Randomized Results of Continuous vs 1-Year Fixed-Duration Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer

Opioid Use and Survival at the End of Life: A Survey of a Hospice Population

Posttraumatic stress disorder (PTSD), anxiety, and depression

XII. HIV/AIDS. Knowledge about HIV Transmission and Misconceptions about HIV

Abstract. Background. Aim. Patients and Methods. Patients. Study Design

Reduced Trauma Symptoms and Perceived Stress in Male Prison Inmates through the Transcendental Meditation Program: A Randomized Controlled Trial

European Journal of Internal Medicine

Assessment of Depression in Multiple Sclerosis. Validity of Including Somatic Items on the Beck Depression Inventory II

A cross-sectional and follow-up study of leukopenia in tuberculosis patients: prevalence, risk factors and impact of anti-tuberculosis

A review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital

Impact of Pharmacist Intervention on Diabetes Patients in an Ambulatory Setting

Schizophrenia Research

Chronic obstructive pulmonary disease (COPD) is the third

Diabetes is a chronic and highly prevalent condition that

Report of the Conference on Low Blood

Effect on Glycemic, Blood Pressure, and Lipid Control according to Education Types

The Relationship of Vitamin D Deficiency to Health Care Costs in Veterans

Colon Cancer Treatment: Are There Racial Disparities in an Equal-Access Healthcare System?

Clinical statistics analysis on the characteristics of pneumoconiosis of Chinese miner population

Lifetime and 12-Month Prevalence of Psychiatric Disorders in 8,169 Male Vietnam War Era Veterans

Ethnic Disparities in Stroke Recognition in Individuals with Prior Stroke

5 WAYS VCARE? What is GLAUCOMA. has earned the highest MEDICAID? Are you on. Are you at Risk? Viva Medicare Plus. to Avoid Hospital Readmissions

Emerging Options for Thromboprophylaxis After Orthopedic Surgery: A Review of Clinical Data

Increased Relative Mortality in Women With Severe Oxygen-Dependent COPD

The Association of Gender With Quality of Health in Peripheral Arterial Disease Following Peripheral Vascular Intervention

Rising costs have led to a number of federal initiatives to

Comparison of claims data on hospitalization rates and repeat procedures in patients receiving a bowel preparation prior to colonoscopy

Overweight can be used as a tool to guide case-finding for cardiovascular risk assessment

Trends in antihypertensive and lipidlowering therapy in subjects with type II diabetes: clinical effectiveness or clinical discretion?

Estimated Prevalence and Economic Burden of Severe, Uncontrolled Asthma in the United States

Epilepsy & Behavior 20 (2011) Contents lists available at ScienceDirect. Epilepsy & Behavior. journal homepage:

Area-Level Socioeconomic Disadvantage and Severe Pulmonary Tuberculosis: U.S.,

Patient Identification. a Yes. a No. Patient: First. Last. Address: Street. Apt. State. City. Zip. Date of Birth: Weight: Age: Race:

A Two-Stage Sampling Method for Clinical Surveillance of Individuals in Care for HIV Infection in the United States

Anemia in pediatric hemodialysis patients: Results from the 2001 ESRD Clinical Performance Measures Project

University of Cape Town

Mental health symptoms and patient-reported diabetes symptom burden: implications for medication regimen changes

Utilization of dental services in Southern China. Lo, ECM; Lin, HC; Wang, ZJ; Wong, MCM; Schwarz, E

ClinicalTrials.gov Identifier: NCT

Inhaled Corticosteroid Is Associated With an Increased Risk of TB in Patients With COPD

Evaluation of Data Obtained from Military Disability Medical Administrative Databases for Service Members with Schizophrenia or Bipolar Disorder

Diabetes affects 29 million Americans, imposing a substantial

Original Article. T Akter 1, N Islam 2, MA Hoque 3, S Khanam 4, HA khan 5, BK Saha 6. Abstract:

Between 45% and 85% of the approximately 4 million people

The Prevalence of Bacteremia in Pediatric Patients With Community-Acquired Pneumonia: Guidelines to Reduce the Frequency of Obtaining Blood Cultures

Original Investigation. management of type 2 diabetes mellitus.

Epidemiological survey and analysis of asthma in children aged 0-14 years old in urban and rural areas of Chengdu region

Efficacy of Sonidegib in Patients With Metastatic BCC (mbcc)

Positive Heparin-Platelet Factor 4 Antibody Complex and Cardiac Surgical Outcomes

Chilblains (pernio, perniosis) are cold-induced, painful or itching

Introduction. These patients benefit less from conventional chemotherapy than patients identified as MMR proficient or microsatellite stable 3-5

SYNOPSIS Final Abbreviated Clinical Study Report for Study CA ABBREVIATED REPORT

HIV Surveillance in Women. National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention Division of HIV/AIDS Prevention

Seasonal influenza vaccination programme country profile: Ireland

The Quality and Outcomes Framework (QOF) is a pay-for-performance

Among US women 65 years and older, the annual

Perforation Following Colorectal Endoscopy: What Happens Beyond the Endoscopy Suite?

Preliminary Findings of a Randomized Controlled Trial of an Interdisciplinary Military Pain Program

Proteinuria Is a Determinant of Quality of Life in Diabetic Nephropathy: Modeling Lagged Effects with Path Analysis

Health-Related Quality of Life and Symptoms of Depression in Extremely Obese Persons Seeking Bariatric Surgery

In 2006, the prevalence of bipolar

Factors affecting screening for hepatocellular carcinoma

Original Article. Breast Care 2016;11: DOI: /

CLINICAL REPORT. Acta Derm Venereol 2015; 95: Line KIBSGAARD 1, Bjørn BAY 2, Mette DELEURAN 1 and Christian VESTERGAARD 1 1

The RUTHERFORD-2 trial in heterozygous FH: Results and implications

MEDALIST Trial Background and Rationale

IMpower133: Primary PFS, OS, and safety in a Ph1/3 study of 1L atezolizumab + carboplatin + etoposide in extensive-stage SCLC

The Effects of Small Sized Rice Bowl on Carbohydrate Intake and Dietary Patterns in Women with Type 2 Diabetes

Invasive Pneumococcal Disease Quarterly Report July September 2018

Psychiatric comorbidity as predictor of costs in back pain patients undergoing disc surgery: a longitudinal observational study

Predictors of Hospitalization in Male Marine Corps Recruits with Exertional Heat Illness

Perioperative Hyperglycemia and Postoperative Infection after Lower Limb Arthroplasty

Reports of cases of AIDS, HIV infection, and HIV/AIDS 1

Work-related musculoskeletal disorders (WMSDs) among nursing personnel

The STAR*D trial is the largest and most consequential antidepressant study

Transcription:

Supplementry Online Content Zulmn DM, Pl Chee C, Ezeji-Okoye SC, et l. Effect of n intensive outptient progrm to ugment primry cre for high-need Veterns Affirs ptients: rndomized clinicl tril. JAMA Intern Med. Published online December 27, 2016. doi:10.1001/jminternmed.2016.8021 etble 1. Chrcteristics of vs. PACT ptients, Engged vs. Non-Engged ptients, nd ptients who responded to the bseline vs. bseline nd follow-up surveys etble 2. Chronic condition dignoses mong vs. PACT ptients, nd Engged vs. Non-Engged ptients efigure 1. Kpln-Meier survivl curves for ptients in nd PACT etble 3. Estimted progrm effects on person-level monthly utiliztion rtes (men, stndrd error) mong intention-to-tret ptients in vs. PACT efigure 2. Estimted monthly person-level totl costs mong intention-to-tret ptients in vs. PACT, during bseline (10/11-1/13) nd follow-up (2/13-6/14) periods etble 4. Estimted progrm effects on monthly person-level costs (men, stndrd error) mong intention-to-tret ptients in vs. PACT etble 5. Estimted progrm effects on monthly person-level costs (men, stndrd error) mong ptients who engged in (tretment on the treted, estimted using rndomiztion s n instrument for prticiption) This supplementry mteril hs been provided by the uthors to give reders dditionl informtion bout their work.

etble 1: Chrcteristics of vs. PACT ptients, Engged vs. Non Engged ptients, nd ptients who responded to the bseline vs. bseline nd follow up surveys Bseline + (n = 140) PACT (n = 405) Engged (n = 96) Non Engged (n = 44) Bseline Survey Only (n = 36) Follow up Survey (n = 54) n (%) n (%) P vlue b n (%) n (%) P vlue b n (%) n (%) P vlue b Age, men (SD) 66.4 (14.0) 65.7 (13.0) 0.62 68.3 (14.2) 62.1 (12.6) 0.01 70.9 (13.4) 67.5 (13.3) 0.24 <30 1 (1) 3 (1) 0 (0) 1 (2) 0 (0) 0 (0) 30 50 12 (9) 27 (7) 8 (8) 4 (9) 1 (3) 5 (9) 51 64 51 (36) 182 (45) 31 (32) 20 (45) 8 (22) 19 (35) 65 74 42 (30) 98 (24) 28 (29) 14 (32) 14 (39) 15 (28) 75 + 34 (24) 95 (24) 29 (30) 5 (11) 13 (36) 15 (27) Mle Sex 130 (93) 365 (90) 0.33 89 (93) 41 (93) 0.92 33 (92) 51 (94) 0.61 Geogrphicl Indictor 0.27 0.04 0.16 Urbn 125 (89) 372 (92) 90 (94) 35 (80) 31 (86) 52 (96) Rurl 11 (8) 29 (7) 4 (4) 7 (16) 4 (11) 1 (2) Unknown 4 (3) 4 (1) 2 (2) 2 (5) 1 (3) 1 (2) Rce/Ethnicity 0.52 0.28 0.22 White, Non Hispnic 79 (56) 240 (59) 58 (60) 21 (48) 23 (64) 30 (56) Blck, Non Hispnic 20 (14) 68 (17) 14 (15) 6 (14) 7 (19) 6 (11) Hispnic 9 (6) 27 (7) 4 (4) 5 (11) 0 (0) 3 (5) Other 32 (23) 70 (17) 20 (21) 12 (27) 6 (16) 15 (28) Chronic Conditions, men (SD) 10.2 (3.5) 10.5 (3.4) 0.38 10.3 (3.5) 10.2 (3.5) 0.94 10.4 (3.7) 9.8 (3.7) 0.44 0 6 18 (13) 46 (11) 12 (13) 6 (14) 5 (14) 8 (15) 7 9 40 (29) 115 (28) 27 (28) 13 (30) 9 (25) 16 (29) 10 12 50 (36) 130 (32) 35 (36) 15 (34) 12 (33) 20 (37) 13 or more 32 (23) 114 (28) 22 (23) 10 (23) 10 (28) 10 (18) Non VA Helth Insurnce (Any) c 74 (53) 224 (55) 0.62 c 57 (59) 17 (39) 0.02 c 24(67) 29(54) 0.22 c Medicre nd/or Med Advntge 69 (49) 205 (51) 54 (56) 15 (34) 22(61) 29(54) Mjor Medicl c 12 (9) 38 (9) 10 (10) 2 (5) 4(11) 5(9) Medicid 4 (3) 10 (2) 3 (3) 1 (2) 1(3) 0(0) All Other 3 (2) 11 (3) 3 (3) 0 (0) 1(3) 2(4) Homelessness (ICD 9 60.0) 35 (25) 104 (26) 0.87 21 (22) 14 (32) 0.21 10 (28) 10 (18) 0.30 CAN Score, men (SD) d 95 (6) 94 (6) 0.44 95 (6) 94 (6) 0.89 95 (5) 94 (6) 0.60 Acute Med/Surg Hosps, men (SD) 1.2 (1.4) 1.2 (1.4) 0.70 1.2 (1.4) 1.1 (1.3) 0.53 2.2 (2) 1.3 (1) 0.01 Emergency Dept Visits, men (SD) 3.4 (3.3) 3.3 (3.3) 0.70 3.5 (3.5) 3.1 (2.9) 0.48 3.4 (3) 3.5 (3) 0.83 Unless otherwise indicted b P vlues reflect t tests for continuous vribles (Age, Chronic Condition Number, CAN Score, Acute Medicl/Surgicl Hospitliztions, Emergency Deprtment Visits) nd chisqure tests for dichotomous/ctegoricl vribles (Sex, Geogrphicl Indictor, Rce/Ethnicity, Homelessness). c Insurnce Sttus ctegories re not mutully exclusive. P vlue reflects chi squre test for the proportion of ptients who hve ny form of helth insurnce outside of VA coverge. Mjor Medicl Insurnce ctegory Includes HMO, PPO, Chmpus, nd Indemnity. d Cre Assessment Need Score (Wng, et l., Medicl Cre, 2013)

etble 2: Chronic condition dignoses mong vs. PACT ptients, nd Engged vs. Non Engged ptients (n=140) PACT (n=405) Engged (n=96) Not Engged (n=44) n (%) n (%) P Vlue n (%) n (%) P Vlue Cncer Cncer (solid/heme cncers, melnom) 29 (21) 112 (28) 0.11 20 (21) 9 (20) 0.96 Crdiovsculr Hypertension 100 (71) 288 (71) 0.94 70 (73) 30 (68) 0.57 Coronry Artery Disese 51 (36) 114 (28) 0.07 36 (38) 15 (34) 0.70 Hert Filure 34 (24) 87 (21) 0.49 25 (26) 9 (20) 0.47 Arrhythmi/Conduction Disorder 46 (33) 150 (37) 0.37 34 (35) 12 (27) 0.34 Cerebrovsculr Disese 18 (13) 55 (14) 0.83 11 (11) 7 (16) 0.47 Vsculr Disese 41 (29) 117 (29) 0.93 32 (33) 9 (20) 0.12 Endocrine/Metbolic/Nutritionl Dibetes Mellitus 47 (34) 152 (38) 0.40 34 (35) 13 (30) 0.50 Lipid Disorders 89 (64) 243 (60) 0.46 62 (65) 27 (61) 0.71 Overweight/Obesity 35 (25) 116 (29) 0.41 25 (26) 10 (23) 0.67 Thyroid Disorders 17 (12) 57 (14) 0.57 11 (11) 6 (14) 0.71 Gstrointestinl Esophgel/Gst/Duod Disorders 63 (45) 178 (44) 0.83 44 (46) 19 (43) 0.77 Liver Disese or Heptitis C 30 (21) 107 (26) 0.24 16 (17) 14 (32) 0.04 Mentl Helth Any Mentl Helth Condition 95 (68) 280 (69) 0.78 62 (65) 33 (75) 0.22 Depression 68 (49) 195 (48) 0.93 47 (49) 21 (48) 0.89 PTSD 32 (23) 115 (28) 0.20 22 (23) 10 (23) 0.98 Anxiety Disorders 20 (14) 86 (21) 0.07 13 (14) 7 (16) 0.71 Bipolr Disorders 12 (9) 25 (6) 0.33 8 (8) 4 (9) 0.88 Personlity Disorders 12 (9) 38 (9) 0.77 6 (6) 6 (14) 0.15 Schizophreni 11 (8) 24 (6) 0.42 5 (5) 6 (14) 0.09 Psychotic Disorders Other 9 (6) 39 (10) 0.25 6 (6) 3 (7) 0.90 Alcohol Use Disorders 30 (21) 103 (25) 0.34 16 (17) 14 (32) 0.04 Drug Use Disorders 41 (29) 102 (25) 0.34 24 (25) 17 (39) 0.10 Musculoskeletl Spine Disorders 65 (46) 187 (46) 0.96 43 (45) 22 (50) 0.57 Joint Disorders 80 (57) 237 (59) 0.78 58 (60) 22 (50) 0.25 Musculoskeletl Conditions Other 73 (52) 188 (46) 0.24 51 (53) 22 (50) 0.73 Neurologic Trumtic Brin Injury 10 (7) 25 (6) 0.69 7 (7) 3 (7) 0.92 Dementi 13 (9) 17 (4) 0.02 8 (8) 5 (11) 0.57 Spinl Cord Injury or Prlysis 5 (4) 16 (4) 0.84 2 (2) 3 (7) 0.16 Peripherl Nerve Disorders 25 (18) 78 (19) 0.72 17 (18) 8 (18) 0.95 Nervous System Sx/Disorders Other 57 (41) 180 (44) 0.44 37 (39) 20 (45) 0.44 Renl/Urinry Renl Filure or Nephropthy 40 (29) 101 (25) 0.40 28 (29) 12 (27) 0.82 Kidney/Ureter/Urinry Conditions 48 (34) 174 (43) 0.07 36 (38) 12 (27) 0.24 Respirtory Chronic Obstructive Pulmonry Disese 34 (24) 76 (19) 0.16 24 (25) 10 (23) 0.77 Asthm 9 (6) 34 (8) 0.46 6 (6) 3 (7) 0.90 Respirtory Conditions Other 82 (59) 248 (61) 0.58 57 (59) 25 (57) 0.78 Hemtologic/Immunologic Anemi 36 (26) 114 (28) 0.58 28 (29) 8 (18) 0.17 Thrombocytopeni 6 (4) 30 (7) 0.20 4 (4) 2 (5) 0.92 Cogultion nd Hem Disorders 5 (4) 20 (5) 0.51 3 (3) 2 (5) 0.67 Hemtologic/Imm Conditions Other 10 (7) 38 (9) 0.42 8 (8) 2 (5) 0.42 P vlues reflect chi squre tests

efigure 1: Kpln Meier survivl curves for ptients in nd PACT Proportion Surviving 0.00 0.25 0.50 0.75 1.00 Kpln-Meier Survivl Curves 0 5 10 15 Months Since PACT Usul Cre

etble 3. Estimted progrm effects on person level monthly utiliztion rtes (men, stndrd error) mong intention to tret ptients in vs. PACT Monthly Utiliztion Utiliztion Mesure D in D Stndrd Error Acute Med/Surg Admissions 0.005 (0.010) Acute Med/Surg Dys 0.035 (0.079) Acute MH Admissions 0.002 (0.005) Acute MH Dys 0.003 (0.079) Extended Med Admissions 0.001 (0.003) Extended Med Dys 0.022 (0.290) Extended MH Admissions 0.002 (0.002) Extended MH Dys 0.131 (0.251) ED Visits 0.008 (0.017) Primry Cre Visits 0.900 (0.094) Specilty Cre Visits 0.053 (0.080) MH Outptient Visits 0.079 (0.100) etble 3 presents estimted progrm effects on person level monthly utiliztion rtes. These effects represent difference indifferences (D in D) mong ll ptients in the intention to tret popultion, which correspond to the chnge in monthly utiliztion mong ptients in, minus the chnge in monthly utiliztion for ptients in PACT. A negtive progrm effect corresponds to lrger decline in utiliztion over the study period mong ptients in, compred to ptients in PACT. Chnges in monthly costs were estimted using liner regression, controlling for ptient fixed effects. MH: Mentl Helth; Acute Med/Surg: medicine/surgery hospitl wrd; Acute MH: cute psychitric hospitl wrd; Extended Med: inptient rehbilittion, extended cre, hospice; Extended MH: inptient mentl helth/ptsd, substnce use rehbilittion, domiciliry, domiciliry/foundtion of recovery; ED: Emergency Deprtment.

efigure 2. Estimted monthly person level totl costs mong intention to tret ptients in vs. PACT, during bseline (10/11 1/13) nd follow up (2/13 6/14) periods Implementtion End of Enrollment PACT Totl costs include ll inptient/outptient/fee bsis costs including costs ssocited with encounters

etble 4. Estimted progrm effects on monthly person level costs (men, stndrd error) mong intention to tret ptients in vs. PACT Inptient Costs Outptient Costs n Totl Inptient Acute Acute Extended Extended ED Primry Fee Bsis Encounter Costs b (All) Med/Surg MH Med MH Visits Cre Specilty MH Costs Costs All ptients 545 101 411 144 59 277 49 5 30** 26 22 92 136 (623) (587) (370) (156) (387) (107) (11) (14) (28) (35) (97) (12) Age under 65 276 922 1375 379 309 724 11 13 35 45 50 45 127 (1014) (911) (574) (288) (586) (229) (19) (21) (39) (65) (75) (18) Age 65 nd older 269 465 412 130 150 65 55 21 27 14 1 123 143 (773) (765) (496) (151) (519) (39) (13) (17) (41) (33) (164) (15) HF/DM/COPD 306 754 993 938 282 394 42 25 27 26 76 172 145 (775) (766) (516) (184) (478) (56) (16) (18) (39) (41) (149) (15) MH dignosis 380 40 252 154 84 88 68 7 25 2 35 146 139 (725) (713) (422) (226) (484) (155) (15) (17) (33) (50) (137) (15) No MH dignosis 165 246 770 112 5 705 3 3 44** 80 6 29 130 (1,202) (1,038) (741) (5) (636) (21) (16) (21) (54) (21) (69) (18) Hospitliztion in 198 908 571 85 310 147 1 24 109** 64 46 172 197 6 mo pre enrollment (1336) (1220) (882) (397) (559) (241) (22) (23) (56) (62) (92) (23) High cost t bseline 356 5 178 244 24 1 83 15 9 14 32 189 121 (828) (808) (506) (230) (550) (160) (14) (17) (38) (47) (142) (14) High risk t bseline 402 4 363 205 88 192 103 8 39** 16 39 5 143 (674) (600) (447) (195) (321) (89) (14) (16) (31) (37) (64) (14) Eligibility: High risk & 657 1119 915 97 379 37 9 18 51 70 25 173 171 hosp 6 mo pre enrollment (1364) (1258) (956) (449) (537) (191) (25) (25) (54) (65) (104) (24) ** p<0.05 HF/DM/COPD: Hert Filure, Dibetes, or Chronic Obstructive Pulmonry Disese; ED: Emergency Deprtment; MH: Mentl Helth; Acute Med/Surg: medicine/surgery hospitl wrd; Acute MH: cute psychitric hospitl wrd; Extended Med: inptient rehbilittion, extended cre, hospice; Extended MH: inptient mentl helth/ptsd, substnce use rehbilittion, domiciliry, domiciliry/foundtion of recovery. Estimted progrm effects represent difference in differences mong ll ptients in the intention to tret popultion, which correspond to the chnge in monthly costs mong ptients in, minus the chnge in costs for ptients in PACT. A negtive progrm effect corresponds to lrger decline in costs over the study period mong ptients in, compred to ptients in PACT. Chnges in monthly costs were estimted using liner regression, controlling for ptient fixed effects. If ptients died or moved wy, their costs were set to 0 nd missing, respectively, for subsequent months. b Totl costs include ll inptient/outptient/fee bsis costs including costs ssocited with encounters (in fr right column)

etble 5. Estimted progrm effects on monthly person level costs (men, stndrd error) mong ptients who engged in (tretment on the treted, estimted using rndomiztion s n instrument for prticiption) Inptient Costs Outptient Costs Impct Totl Costs b Inptient (All) Acute Med/Surg Acute MH Extended MED Extended MH ED Visits Primry Cre Outptient Specilty Outptient MH Fee Bsis Costs Encounter Costs All ptients 145 588 206 84 397 71 8 44** 37 32 132 194 (842) (870) (481) (217) (506) (178) (14) (17) (37) (51) (155) (14) Age under 65 1466 2185 603 492 1150 17 21 57 71 79 71 202 (1402) (1491) (932) (452) (891) (371) (30) (33) (66) (91) (114) (26) Age 65 nd older 806 547 173 199 86 74 28** 36 18 2 163 189 (1175) (1012) (714) (199) (818) (63) (14) (20) (56) (37) (188) (17) HF/DM/COPD 1057 1392 1,314 395 552 59 35 38 37 106 240 203 (1029) (867) (674) (258) (712) (64) (22) (27) (58) (58) (187) (18) MH dignosis 61 380 232 127 132 103 10 37 3 53 221 209 (929) (1145) (695) (355) (624) (211) (21) (23) (46) (68) (196) (16) No MH dignosis 317 991 145 7 908 4 3 56** 103 8 37 167 (1508) (1505) (870) (5) (848) (26) (21) (30) (67) (25) (107) (14) Hospitliztion in 255 1171 736 110 400 190 2 31 141 82 60 222 6 mo pre enrollment (1870) (1555) (1187) (432) (680) (366) (33) (25) (78) (72) (117) (24) High cost t bseline 8 266 363 36 1 123 23 13 21 48 281 180 (1160) (1122) (796) (340) (884) (249) (20) (25) (52) (64) (231) (14) High risk t bseline 6 515 291 125 273 147 11 55** 22 55 7 203 (1051) (855) (692) (292) (446) (148) (20) (24) (38) (48) (81) (18) Eligibility: High risk & 851 1450 1185 125 491 48 11 24 66 90 32 223 hosp 6 mo pre enrollment (1652) (1804) (1297) (630) (712) (253) (37) (33) (63) (97) (152) (26) ** p<0.05 HF/DM/COPD: Hert Filure, Dibetes, or Chronic Obstructive Pulmonry Disese; ED: Emergency Deprtment; MH: Mentl Helth; Acute Med/Surg: medicine/surgery hospitl wrd; Acute MH: cute psychitric hospitl wrd; Extended Med: inptient rehbilittion, extended cre, hospice; Extended MH: inptient mentl helth/ptsd, substnce use rehbilittion, domiciliry, domiciliry/foundtion of recovery. Estimted progrm effects represent difference in differences for ptients who engged in, which correspond to the chnge in monthly costs mong ptients in, minus the chnge in costs for ptients in PACT. A negtive progrm effect corresponds to lrger decline in costs over the study period mong ptients in, compred to ptients in PACT. Chnges in monthly costs were estimted using liner regression, controlling for ptient fixed effects. If ptients died or moved wy, their costs were set to 0 nd missing, respectively, for subsequent months. b Includes ll inptient/outptient/fee bsis costs including costs ssocited with encounters (in fr right column) etble 5 reports results from secondry nlyses in which we estimted the effect of the intervention on ptients who ctively engged in (defined priori s completing n intke nd t lest three dditionl encounters) using rndomiztion s n instrument for prticiption. These nlyses re in contrst to the intention to tret nlyses presented in etble 4, where we estimted the effect of being rndomized to receive. As expected, we estimte effects tht re modestly lrger thn those from the intention to tret nlyses.